
[Expand/Collapse all sections]Expand all

This document outlines details of the PBS-subsidised brentuximab vedotin
and vorinostat for patients with cutaneous T-cell lymphoma (CTCL), and
brentuximab vedotin for patients with peripheral T-cell lymphoma (PTCL).

T-Cell lymphoma and listing dates

Peripheral T-cell lymphoma refers to a group of T-cell lymphomas that
develop away from the thymus or bone marrow.

Cutaneous T-cell lymphoma (CTCL) is a specific type of PTCL where the
cells attack the skin.

Listing dates are:

-   vorinostat - 1 July 2017
-   brentuximab vedotin - 1 April 2019 (CTCL)
-   brentuximab vedotin - 1 September 2021 (PTCL)

For more information, see Written Authority Required Drugs.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, contact details,
item and restriction codes, FAQs, the PBS schedule and the Services
Australia websites.

Related links

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
